Soleno Therapeutics, Inc. (SLNO)
NASDAQ: SLNO · Real-Time Price · USD
57.05
-0.06 (-0.11%)
Nov 8, 2024, 4:00 PM EST - Market closed
Soleno Therapeutics Employees
Soleno Therapeutics had 33 employees as of December 31, 2023. The number of employees increased by 8 or 32.00% compared to the previous year.
Employees
33
Change (1Y)
8
Growth (1Y)
32.00%
Revenue / Employee
n/a
Profits / Employee
-$3,974,667
Market Cap
2.46B
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Azenta | 3,500 |
Warby Parker | 3,473 |
Premier | 2,900 |
Tandem Diabetes Care | 2,400 |
LeMaitre Vascular | 630 |
Clover Health Investments | 552 |
RxSight | 374 |
Wave Life Sciences | 268 |
SLNO News
- 4 weeks ago - Soleno Therapeutics Nears FDA Decision: Strong Buy Targeting PWS Hyperphagia Treatments - Seeking Alpha
- 4 weeks ago - SLNO Stock Rises as Prader-Willi Treatment Nears FDA Approval - GuruFocus
- 5 weeks ago - Janus Henderson Group PLC's Strategic Acquisition in Soleno Therapeutics Inc - GuruFocus
- 7 weeks ago - Soleno Therapeutics to Present at 2024 Cantor Global Healthcare Conference - GlobeNewsWire
- 2 months ago - Soleno Therapeutics: 2 New Catalysts To Bring Forth Change For PWS Patients - Seeking Alpha
- 2 months ago - Soleno Therapeutics Announces U.S. FDA Acceptance for Filing and Priority Review of NDA for DCCR (Diazoxide Choline) Extended-Release Tablets in Prader-Willi Syndrome - GlobeNewsWire
- 2 months ago - Soleno Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 4 months ago - Soleno Therapeutics Announces Submission of New Drug Application to the U.S. FDA for DCCR (Diazoxide Choline) Extended-Release Tablets for the Treatment of Prader-Willi Syndrome - GlobeNewsWire